College Prep English at EIE May 29, 2014
Oratory practice: discussion of genetic engineering.

By: Abacus Ed

See more here:
College Prep English at EIE May 29, 2014 - Video

Humans have been manipulating crop genetics for thousands of years, crossing and selecting plants that exhibit desirable traits. In the last century, breeders exposed crops to radiation and chemicals that induced random mutations. These and other lab methods gave fruits and vegetables new colors, made crops disease resistant and made grains easier to harvest. Most wheat, rice and barley are descendants of mutant varieties, as are many vegetables and fruits. Hello, Star Ruby grapefruit! In the early 1980s, scientists discovered how to insert genes from other species into plants. The process led to the 1994 commercialization of the first GMO, the Flavr Savr tomato. It was tasteless and was pulled from the market. No GMO meat is currently for sale, though not for lack of trying. AquaBounty Technologies has been trying for 19 years to win approval for salmon engineered to grow twice as fast as conventional salmon, with less feed. The 1995 application remains pending before the U.S. Food and Drug Administration, which has determined the fish is safe to consume. Advocates want it labeled.

Read more here:
Engineered Food

PUBLIC RELEASE DATE:

30-May-2014

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, May 30, 2014High throughput screening of compounds in live cells is a powerful approach for discovering new drugs, but the potential for cell toxicity must be considered. A novel technique that uses DNA-binding fluorescent dyes to evaluate the cytotoxicity of an experimental compound in real-time during screening, saving time and resources, is described in ASSAY and Drug Development Technologies, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available on the ASSAY and Drug Development Technologies website.

Lucius Chiaraviglio and James Kirby, Beth Israel Deaconess Medical Center, evaluated 19 fluorescent DNA-binding dyes and identified four dyes that were not harmful to cells and could not cross the cell membrane if a cell was viable. The authors demonstrated the ability to use these dyes to detect cell death during drug screening in the article "Evaluation of Impermeant, DNA-Binding Dye Fluorescence as a Real-Time Readout of Eukaryotic Cell Toxicity in a High Throughput Screening Format."

###

About the Journal

Assay and Drug Development Technologies is an authoritative peer-reviewed journal published 10 times a year in print and online. It provides early-stage screening techniques and tools that enable identification and optimization of novel targets and lead compounds for new drug development. Complete tables of content and a complementary sample issue may be viewed on the ASSAY and Drug Development Technologies website.

About the Publisher

Mary Ann Liebert, Inc., publishers, is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many areas of science and biomedical research, including OMICS: A Journal of Integrative Biology and Genetic Testing and Molecular Biomarkers. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

More:
DNA-binding fluorescent dyes detect real-time cell toxicity during drug screening

With a little genetic engineering, the vaccine that was key in helping eradicate smallpox more than 30 years ago could also be key in curing cancer, if a young Cleveland biotech has anything to say about it.

Western Oncolytics is developing a dual-mechanism therapy that combines oncolytic virus and gene therapy technologies with the hope of wiping out the ability of cancer cells to survive in the body.

CEO Kurt Rote is a first-time entrepreneur, but you wouldnt know it from talking to him. After getting a biomedical engineering degree from Duke and moving to Switzerland to get an MBA, he worked for a short time at a small biotech firm before deciding to risk everything to realize a personal dream of curing cancer.

In pursuit of bleeding-edge technology, he started making calls to university researchers.I went down a list of NIH grants and talked to as many of them as possible, he said. I wanted to go where the science led me.

Where it led him was to the office of Stephen H. Thorne at the University of Pittsburgh Cancer Center, who had been studying oncolytic viruses for years.

Oncolytic viruses are genetically modified to infect and kill cancer cells while simultaneously triggering an anti-tumor immune response. Their promise lies in being able to treat cancers with side effects that parallel those of a flu shot, rather than those from chemotherapy.

Although theyve been studied for decades, theyre just now advancing to the point where theyre being tested in large-scale human trials. Amgen recently completed a Phase 3 study in melanoma patients of an oncolytic virus it bought from Biovex in a 2011 deal worth up to $1 billion. The results of the trial were mixed, potentially limiting the commercial viability of the drug, but the trial serves as an important milestone for the field.

The therapy developed in Thornes lab employs similar concepts but is based on more advanced technology and has shown better tumor shrinkage and remission in animal testing, Rote said.

A number of different elements work together in the vaccine. It contains the vaccinia virus (used in the smallpox vaccine) with three gene modifications: the addition of two that signal T-cells to come to the tumor and reduce the number of immune suppressor cells in the tumor, respectively, and the deletion of a viral gene which leads to infected cells sending more signals to the immune system.

And, to avoid the immune system from being triggered immediately, before the virus reaches the tumor, scientists have modified its surface to delay the immune response.

Visit link:
Virus that helped eradicate smallpox takes on cancer in startups dual-mechanism immunotherapy